Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...
Robert Weinstein Exchange Commission Drug Administration Prnewswire Synaptogenix Inc Synaptogenix Inc Advanced Alzheimer
Source: prnewswire.com